1,2-dioleoyl-sn-glycero-3-phosphate | 61617-08-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 英文名称: 1,2-dioleoyl-sn-glycero-3-phosphate
• 英文别名: dioleoyl phosphatidic acid；Dioleoyl-L-alpha-phosphatidic acid；1,2-Dioleoyl-sn-glycerol-3-phosphate；[(2R)-2-[(Z)-octadec-9-enoyl]oxy-3-phosphonooxypropyl] (Z)-octadec-9-enoate
• CAS: 61617-08-1
• 化学式: C₃₉H₇₃O₈P
• 分子量: 700.978
• InChiKey: MHUWZNTUIIFHAS-DSSVUWSHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  13.2
• 重原子数：
  48
• 可旋转键数：
  38
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.85
• 拓扑面积：
  119
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  1,2-dioleoyl-sn-glycero-3-phosphate 在 正己烷 、 溶剂黄146 、 铂 作用下， 生成 1,2-Distearoyl-sn-glycero-3-phosphoric acid
  参考文献：
  名称：

  Baer; Buchnea, Archives of Biochemistry, 1958, vol. 78, p. 294,301

  摘要：

  DOI：
• 作为产物：
  描述：

  1,2-二油酰基-sn-甘油 在 三氯氧磷 作用下， 以 1,2-二氯乙烷 为溶剂， 以76 %的产率得到1,2-dioleoyl-sn-glycero-3-phosphate
  参考文献：
  名称：

  一种磷脂酸的制备工艺

  摘要：

  本发明属于有机合成技术领域，具体涉及一种磷脂酸的制备方法。本发明提供的磷脂酸的制备方法，包括以下步骤：(R)‑3‑氯‑1,2‑丙二醇与第一酰基化试剂进行第一酰基化反应，得到(R)‑3‑氯‑2‑羟基脂肪酸酯；再将其进行第二酰基化反应，得到(R)‑3‑氯‑1,2‑脂肪酸二酯；进而与苯甲醇发生取代反应后脱去苄基，最后进行磷酸酯化反应即可制备纯度≥98％的磷脂酸。本发明的工艺简洁，条件温和，适合工业化制备。

  公开号：

  CN115010749A

文献信息

• FLUORESCENT ANTICANCER PLATINUM DRUGS
  申请人：INVICTUS ONCOLOGY PVT. LTD.

  公开号：US20180312534A1

  公开（公告）日：2018-11-01

  The present disclosure is in relation to the field of nanotechnology and cancer therapeutics. In particular, the present disclosure relates to fluorescent platinum based compounds. The disclosure further relates to synthesis of said fluorescent platinum based compounds, nanoparticles and compositions comprising said fluorescent platinum based compounds/nanoparticles. The disclosure also relates to methods of managing cancer by the fluorescence changes between aforesaid platinum based compounds and corresponding free ligands, nanoparticles and compositions.

  本公开涉及纳米技术和癌症治疗领域。具体而言，本公开涉及荧光铂基化合物。该公开进一步涉及合成所述荧光铂基化合物、纳米颗粒和包含所述荧光铂基化合物/纳米颗粒的组合物。该公开还涉及通过上述铂基化合物与相应的游离配体、纳米颗粒和组合物之间的荧光变化来管理癌症的方法。
• Growth Hormone Secretagogue Receptor 1A Ligands
  申请人：Schambye Hans T.

  公开号：US20080300180A1

  公开（公告）日：2008-12-04

  The present invention relates to new growth hormone secretagogue receptor 1A (GHS-R 1A) ligands, and pharmaceutical compositions comprising any of the new GHS-R1 A ligands. The ligands are suitable for a wide range of applications, and thus the present invention also relates to use of the GHS-R1 A ligands according to the present invention in the manufacture of a medicament for the treatment of an individual in need thereof. In another aspect, the present invention relates to a method of treatment of an individual in need thereof, comprising administering to said individual one or more of the GHS-R1A ligands disclosed herein, such as e.g. for treatment of cancer cachexia.

  本发明涉及新型生长激素促分泌素受体1A（GHS-R 1A）配体，以及包含任何此类新型GHS-R1A配体的药物组合物。这些配体适用于广泛的应用范围，因此本发明还涉及根据本发明的GHS-R1A配体在制造用于治疗有此需要的个体的药物中的用途。在另一方面，本发明涉及一种治疗有此需要的个体的方法，包括向该个体施用本文披露的一种或多种GHS-R1A配体，例如用于治疗癌症恶病质。
• Amine Cationic Lipids and Uses Thereof
  申请人：Dicerna Pharmaceuticals, Inc.

  公开号：US20140371293A1

  公开（公告）日：2014-12-18

  The present invention relates to lipid compounds and uses thereof. In particular, the compounds include a class of cationic lipids having an amine moiety, such as an amino-amine or an amino-amide moiety. The lipid compounds are useful for in vivo or in vitro delivery of one or more agents (e.g., a polyanionic payload or an antisense payload, such as an RNAi agent).

  本发明涉及脂质化合物及其用途。具体而言，这些化合物包括一类具有胺基团的阳离子脂质，例如氨基-胺或氨基-酰胺基团。这些脂质化合物可用于体内或体外传递一个或多个药物（例如，多聚阴离子荷载物或反义荷载物，如RNAi药物）。
• HYDROPHILIC FLUORINATED MOLECULES FOR LIPOSOMAL 19F MRI PROBES WITH UNIQUE MR SIGNATURES
  申请人：TEXAS CHILDREN'S HOSPITAL

  公开号：US20180154025A1

  公开（公告）日：2018-06-07

  Readily available hydrophilic and small organofluorine moieties were condensed via “click chemistry” to generate nonionic hydrophilic fluorinated molecules with unique 19 F MR signatures. These were used to fabricate stable liposome formulations for imaging various tissue types. This approach was tailored to exploit the broad spectrum of organic 19 F molecular species and to generate probes with distinct 19 F MRI signatures for simultaneous assessment of multiple molecular targets within the same target volume.

  通过“点击化学”将易得的亲水性和小的有机氟基团缩合，生成具有独特的19F MR标记的非离子亲水性氟化分子。这些分子被用于制备稳定的脂质体配方，用于成像各种组织类型。这种方法旨在利用有机19F分子种类的广泛谱，生成具有不同19F MRI标记的探针，以同时评估同一目标体积内多个分子靶标。
• [EN] NEAR INFRARED FLUORESCENT DYES, FORMULATIONS AND RELATED METHODS<br/>[FR] COLORANTS FLUORESCENTS DANS L'INFRAROUGE PROCHE, FORMULATIONS ET PROCÉDÉS ASSOCIÉS
  申请人：UNIV WASHINGTON

  公开号：WO2021119423A1

  公开（公告）日：2021-06-17

  Provided herein is a pharmaceutical composition comprising an effective amount of cypate-Cyclo(Cys-Gly-Arg-Asp-Ser-Pro-Cys)-Lys-OH (LS301), cypate-Cyclo(Cys-Gly-Arg-Asp- Ser-Pro-Cys)-Tyr-OH (LS838) or pharmaceutically acceptable salts thereof, wherein each amino acid residue is independently in a D or L configuration; a divalent metal ion; and a pharmaceutically acceptable carrier. Further provided are lyophilized products comprising a dye-conjugate and m methods for identifying compromised and for binding phosphorylated annexin A2 (pANXA2) protein in a biological sample using a composition described herein.

  本文提供了一种药物组合物，包括有效量的cypate-Cyclo(Cys-Gly-Arg-Asp-Ser-Pro-Cys)-Lys-OH（LS301）、cypate-Cyclo(Cys-Gly-Arg-Asp-Ser-Pro-Cys)-Tyr-OH（LS838）或其药用盐，其中每个氨基酸残基独立地处于D或L构型；一种二价金属离子；和一种药用可接受的载体。此外，还提供了含有染料结合物的冻干产品，以及使用上述组合物的方法来识别生物样本中受损并结合磷酸化的A2型附着蛋白（pANXA2）蛋白。